[1] 陈伟伟,高润霖,刘力生,等.《中国心血管病报告2017》概要[J].中国循环杂志, 2018,33(1):1-8.[2] Chi HJ, Chen ML, Yang XC, et al. Progress in Therapies for Myocardial Ischemia Reperfusion Injury. Curr Drug Targets. 2017;18(15):1712-1721. [3] Zhou T, Chuang CC, Zuo L. Molecular Characterization of Reactive Oxygen Species in Myocardial Ischemia-Reperfusion Injury. Biomed Res Int. 2015;2015:864946.[4] Okafor ON, Farrington K, Gorog DA. Allopurinol as a therapeutic option in cardiovascular disease. Pharmacol Ther. 2017;172:139-150.[5] Wang F, Liang GY, Liu DX, et al. Effect of Si-RNA-silenced HIF-1α gene on myocardial ischemia-reperfusion-induced insulin resistance. Int J Clin Exp Med. 2015;8(9):15514-15520.[6] Garcia-Dorado D, Ruiz-Meana M, Inserte J, et al. Calcium-mediated cell death during myocardial reperfusion. Cardiovasc Res. 2012;94(2): 168-180.[7] Chouchani ET, Pell VR, Gaude E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515(7527):431-435.[8] 陈福晖,刘达兴,容松.心肌缺血再灌注损伤发生机制的研究进展[J].安徽医药,2017, 21(12): 2145-2148.[9] 叶明,吴辉.心肌缺血再灌注损伤的研究新进展[J].中华老年心脑血管病杂志, 2016, 18(4): 434-437.[10] Tao H, Nuo M, Min S. Sufentanil protects the rat myocardium against ischemia-reperfusion injury via activation of the ERK1/2 pathway . Cytotechnology. 2018;70(1):169-176.[11] Li Y, Jiang T, Fu X, et al. Atorvastatin protects cardiomyocytes against OGD/R?induced apoptosis by inhibiting miR?199a?5p. Mol Med Rep. 2017;16(4):3807-3816.[12] Penn MS, Dong F, Klein S, et al. Stem cells for myocardial regeneration. Clin Pharmacol Ther. 2011;90(4):499-501.[13] 王娟,贾合磊,吉红亮,等.同种异体骨髓间充质干细胞移植在心肌梗死后心室重建中的作用[J].中国组织工程研究, 2016, 20(50): 7487-7493.[14] Karantalis V, Suncion-Loescher VY, Bagno L, et al. Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy. J Am Coll Cardiol. 2015;66(18):1990-1999.[15] Charwat S, Gyöngyösi M, Lang I, et al. Role of adult bone marrow stem cells in the repair of ischemic myocardium: current state of the art. Exp Hematol. 2008;36(6):672-680.[16] Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells. 2010;28(3):585-596.[17] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.[18] Li X, Yu X, Lin Q, et al. Bone marrow mesenchymal stem cells differentiate into functional cardiac phenotypes by cardiac microenvironment. J Mol Cell Cardiol. 2007;42(2):295-303.[19] Niu H, Mu J, Zhang J, et al. Comparative study of three types of polymer materials co-cultured with bone marrow mesenchymal stem cells for use as a myocardial patch in cardiomyocyte regeneration. J Mater Sci Mater Med. 2013;24(6):1535-1542.[20] Gao S, Zhao Z, Wu R, et al. Bone marrow mesenchymal stem cell transplantation improves radiation-induced heart injury through DNA damage repair in rat model. Radiat Environ Biophys. 2017;56(1):63-77.[21] Humphreys BD, Bonventre JV. Mesenchymal stem cells in acute kidney injury. Annu Rev Med. 2008;59:311-325.[22] Wen Z, Zheng S, Zhou C, et al. Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. J Cell Mol Med. 2011;15(5):1032-1043.[23] 丁国永,郭丽,杜忠君,等.骨髓间充质干细胞对肾缺血再灌注损伤后肾功能及氧化应激水平的改善作用[J].吉林大学学报(医学版), 2009, 35(4): 587-590,572.[24] 刘煜昊,房佰俊,史明霞,等.人骨髓间充质干细胞在体内外分化为心血管组织[J].基础医学与临床, 2007,27(6):643-647.[25] He JG, Xie QL, Li BB, et al. Exosomes Derived from IDO1-Overexpressing Rat Bone Marrow Mesenchymal Stem Cells Promote Immunotolerance of Cardiac Allografts. Cell Transplant. 2018. doi: 10.1177/0963689718805375. [Epub ahead of print][26] Rombouts WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia. 2003;17(1):160-170.[27] Honczarenko M, Le Y, Swierkowski M, et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells. 2006;24(4):1030-1041.[28] Bao L, Meng Q, Li Y, et al. C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner. J Card Fail. 2017;23(5):403-415.[29] Suzuki E, Fujita D, Takahashi M, et al. Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes in Cardiovascular Disease. Adv Exp Med Biol. 2017;998:179-185.[30] Henning RJ. Current status of stem cells in cardiac repair. Future Cardiol. 2018;14(2):181-192.[31] Kishore R, Khan M. More Than Tiny Sacks: Stem Cell Exosomes as Cell-Free Modality for Cardiac Repair. Circ Res. 2016;118(2):330-343.[32] Suzuki E, Fujita D, Takahashi M, et al. Stem cell-derived exosomes as a therapeutic tool for cardiovascular disease. World J Stem Cells. 2016; 8(9):297-305.[33] Gong M, Yu B, Wang J, et al. Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis. Oncotarget. 2017;8(28):45200-45212.[34] Zhang MQ, Chen H, Zhai CL, et al. Follistatin-like 1-engineered mesenchymal stem cells prevent myocardial ischemic reperfusion injury. Zhonghua Yi Xue Za Zhi. 2016;96(25):2017-2022.[35] Liu JF, Ling B. Bone marrow-derived mesenchymal stem cells in the treatment of myocardial infarction. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015;37(1):108-112.[36] Jacobs SA, Roobrouck VD, Verfaillie CM, et al. Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol. 2013;91(1):32-39.[37] Ruggeri L, Mancusi A, Burchielli E, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2008;40(1):84-90.[38] Wu T, Liu Y, Fan Z, et al. miR-21 Modulates the Immunoregulatory Function of Bone Marrow Mesenchymal Stem Cells Through the PTEN/Akt/TGF-β1 Pathway. Stem Cells. 2015;33(11):3281-3290.[39] 巫宏坤,梁贵友,余丽梅,等.人羊膜间充质干细胞移植对犬体外循环再灌注肺损伤的影响[D]. 遵义:遵义医学院, 2016.[40] Ong SB, Subrayan S, Lim SY, et al. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121(18):2012-2022.[41] Matsui Y, Takagi H, Qu X, et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res. 2007;100(6):914-922.[42] Zhang Z, Yang C, Shen M, et al. Autophagy mediates the beneficial effect of hypoxic preconditioning on bone marrow mesenchymal stem cells for the therapy of myocardial infarction. Stem Cell Res Ther. 2017;8(1):89.[43] Jin Y, Wang H, Cui X, et al. Role of autophagy in myocardial reperfusion injury. Front Biosci (Elite Ed). 2010;2:1147-1153.[44] 赵海洋,张佳运,程姝娟.自噬在急性心肌梗死后无复流中的表达[J].广东医学,2016,37(11):1628-1630.[45] Cui X, He Z, Liang Z, et al. Exosomes From Adipose-derived Mesenchymal Stem Cells Protect the Myocardium Against Ischemia/Reperfusion Injury Through Wnt/β-Catenin Signaling Pathway. J Cardiovasc Pharmacol. 2017;70(4):225-231.[46] Liu L, Jin X, Hu CF, et al. Exosomes Derived from Mesenchymal Stem Cells Rescue Myocardial Ischaemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy Via AMPK and Akt Pathways. Cell Physiol Biochem. 2017;43(1):52-68.[47] Zhang Z, Yang M, Wang Y, et al. Autophagy regulates the apoptosis of bone marrow-derived mesenchymal stem cells under hypoxic condition via AMP-activated protein kinase/mammalian target of rapamycin pathway. Cell Biol Int. 2016;40(6):671-685.[48] Matsui Y, Kyoi S, Takagi H, et al. Molecular mechanisms and physiological significance of autophagy during myocardial ischemia and reperfusion. Autophagy. 2008;4(4):409-415.[49] 张文静,崔丽艳,张捷.自噬与缺血再灌注损伤[J].检验医学, 2014,29(2): 182-185.[50] Valentim L, Laurence KM, Townsend PA, et al. Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. J Mol Cell Cardiol. 2006;40(6): 846-852.[51] Maslov LN, Podoksenov IuK, Portnichenko AG, et al. Hypoxic preconditioning of stem cells as a new approach to increase the efficacy of cell therapy for myocardial infarction. Vestn Ross Akad Med Nauk. 2013;(12):16-25.[52] Hu C, Li L. Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. J Cell Mol Med. 2018;22(3):1428-1442.[53] Epstein SE, Luger D, Lipinski MJ. Paracrine-Mediated Systemic Anti-Inflammatory Activity of Intravenously Administered Mesenchymal Stem Cells: A Transformative Strategy for Cardiac Stem Cell Therapeutics. Circ Res. 2017;121(9):1044-1046.[54] Florea V, Rieger AC, DiFede DL, et al. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study). Circ Res. 2017;121(11): 1279-1290.[55] Ciuffreda MC, Malpasso G, Chokoza C, et al. Synthetic extracellular matrix mimic hydrogel improves efficacy of mesenchymal stromal cell therapy for ischemic cardiomyopathy. Acta Biomater. 2018;70:71-83.[56] Elmadbouh I, Ashraf M. Tadalafil, a long acting phosphodiesterase inhibitor, promotes bone marrow stem cell survival and their homing into ischemic myocardium for cardiac repair. Physiol Rep. 2017;5(21): e13480. |